PAVmed subsidiary Veris Health partners with Ohio State University cancer center

Yahoo

3 days ago

PAVmed's (PAVM) majority-owned digital health subsidiary Veris Health has entered into a strategic partnership agreement with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, or OSUCCC – James, a National Cancer Institute-Designated Comprehensive Cancer Center. This agreement follows the successful completion of a pilot program which enrolled patients across several OSUCCC – James cancer care service lines on the Veris Cancer Care Platform. Veris and OSUCCC – James entered into a long-term, multi-project strategic partnership to utilize, and further the development and commercialization of the Veris Cancer Care Platform and its implantable physiologic monitor. The agreement includes expansion of commercial utilization of the platform across cancer care service lines; full electronic health record integration; initiation of a clinical registry of patients enrolled on the platform to be launched in the coming weeks; and launch of a clinical trial of patients receiving the implantable physiologic monitor, to be launched upon FDA clearance, expected next year. Cancer patients enrolled on the platform receive a VerisBox of Veris-branded connected health care devices which transmit physiologic data to the cloud-based clinician portal via embedded cellular connections.
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PAVM:
Disclaimer & DisclosureReport an Issue
Lucid Diagnostics to join Russell 2000, Russell 3000 indexes
PAVmed's Earnings Call: Optimism Amid Challenges
PAVmed's Strategic Advancements and Growth Potential Drive Buy Rating
Pavmed Inc. Reports Turnaround with Strong Q1 Earnings
PAVmed Reports Q1 2025 Financial Results and Updates